Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of BioAtla Inc (NASDAQ: BCAB) closed at $1.57 in the last session, up 12.95% from day before closing price of $1.39. In other words, the price has increased by $12.95 from its previous closing price. On the day, 1.56 million shares were traded. BCAB stock price reached its highest trading level at $1.9 during the session, while it also had its lowest trading level at $1.37.
Ratios:
We take a closer look at BCAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.11 and its Current Ratio is at 3.11. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.00.
On September 15, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $17.
Credit Suisse Downgraded its Outperform to Neutral on May 05, 2022, whereas the target price for the stock was revised from $35 to $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 26 ’23 when MCBRINN SYLVIA bought 4,000 shares for $2.33 per share. The transaction valued at 9,320 led to the insider holds 15,125 shares of the business.
SHORT JAY M PHD bought 50,000 shares of BCAB for $106,910 on Dec 20 ’23. The Chief Executive Officer now owns 1,439,283 shares after completing the transaction at $2.14 per share. On Dec 19 ’23, another insider, STEINMAN LAWRENCE, who serves as the Director of the company, bought 20,000 shares for $2.05 each. As a result, the insider paid 41,048 and bolstered with 38,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAB now has a Market Capitalization of 75902592 and an Enterprise Value of 20637550. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.79 while its Price-to-Book (P/B) ratio in mrq is 3.30. Its current Enterprise Value per Revenue stands at 1.876 whereas that against EBITDA is -0.242.
Stock Price History:
Over the past 52 weeks, BCAB has reached a high of $4.02, while it has fallen to a 52-week low of $1.14. The 50-Day Moving Average of the stock is -16.68%, while the 200-Day Moving Average is calculated to be -25.67%.
Shares Statistics:
According to the various share statistics, BCAB traded on average about 1.17M shares per day over the past 3-months and 1546070 shares per day over the past 10 days. A total of 48.08M shares are outstanding, with a floating share count of 39.02M. Insiders hold about 19.30% of the company’s shares, while institutions hold 32.54% stake in the company. Shares short for BCAB as of 1730332800 were 4868885 with a Short Ratio of 4.15, compared to 1727654400 on 4466935. Therefore, it implies a Short% of Shares Outstanding of 4868885 and a Short% of Float of 11.26.
